Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 14 entries
Sorted by: Best Match Show Resources per page
Long-Term Suture Breakage After Scleral Fixation of a Modified Capsular Tension Ring with Polypropylene 10-0 Suture.

Clinical ophthalmology (Auckland, N.Z.)

Kristianslund O, Sandvik GF, Drolsum L.
PMID: 34163130
Clin Ophthalmol. 2021 Jun 14;15:2473-2479. doi: 10.2147/OPTH.S310648. eCollection 2021.

AIM: To investigate the long-term risk of suture breakage after implantation of a modified capsular tension ring (MCTR) fixated to the sclera with polypropylene 10-0 suture.METHODS: Retrospective case series of operations for subluxated phakic lenses in 2007-2015 with implantation...

Cite
Kristianslund O, Sandvik GF, Drolsum L. Long-Term Suture Breakage After Scleral Fixation of a Modified Capsular Tension Ring with Polypropylene 10-0 Suture. Clin Ophthalmol. 2021;15:2473-2479doi: 10.2147/OPTH.S310648.
Kristianslund, O., Sandvik, G. F., & Drolsum, L. (2021). Long-Term Suture Breakage After Scleral Fixation of a Modified Capsular Tension Ring with Polypropylene 10-0 Suture. Clinical ophthalmology (Auckland, N.Z.), 152473-2479. https://doi.org/10.2147/OPTH.S310648
Kristianslund, Olav, et al. "Long-Term Suture Breakage After Scleral Fixation of a Modified Capsular Tension Ring with Polypropylene 10-0 Suture." Clinical ophthalmology (Auckland, N.Z.) vol. 15 (2021): 2473-2479. doi: https://doi.org/10.2147/OPTH.S310648
Kristianslund O, Sandvik GF, Drolsum L. Long-Term Suture Breakage After Scleral Fixation of a Modified Capsular Tension Ring with Polypropylene 10-0 Suture. Clin Ophthalmol. 2021 Jun 14;15:2473-2479. doi: 10.2147/OPTH.S310648. eCollection 2021. PMID: 34163130; PMCID: PMC8214109.
Copy Download .nbib Format: NLM
Pupillary response in adults with Marfan syndrome and its effect on straylight.

Acta ophthalmologica

Sandvik GF, Rand-Hendriksen S, Drolsum L, Kristianslund O.
PMID: 34890490
Acta Ophthalmol. 2021 Dec 10; doi: 10.1111/aos.15079. Epub 2021 Dec 10.

PURPOSE: The main objective of this study was to examine the pupillary response in patients with Marfan syndrome (MFS) and secondarily to determine whether changes in the pupillary response are associated with the increased disability glare previously shown in...

Cite
Sandvik GF, Rand-Hendriksen S, Drolsum L, et al. Pupillary response in adults with Marfan syndrome and its effect on straylight. Acta Ophthalmol. 2021;doi: 10.1111/aos.15079.
Sandvik, G. F., Rand-Hendriksen, S., Drolsum, L., & Kristianslund, O. (2021). Pupillary response in adults with Marfan syndrome and its effect on straylight. Acta ophthalmologica, . https://doi.org/10.1111/aos.15079
Sandvik, Gunhild Falleth, et al. "Pupillary response in adults with Marfan syndrome and its effect on straylight." Acta ophthalmologica vol. (2021). doi: https://doi.org/10.1111/aos.15079
Sandvik GF, Rand-Hendriksen S, Drolsum L, Kristianslund O. Pupillary response in adults with Marfan syndrome and its effect on straylight. Acta Ophthalmol. 2021 Dec 10; doi: 10.1111/aos.15079. Epub 2021 Dec 10. PMID: 34890490.
Copy Download .nbib Format: NLM
Implantation of retropupillary iris-claw lenses: A review on surgical management and outcomes.

Acta ophthalmologica

Drolsum L, Kristianslund O.
PMID: 33683012
Acta Ophthalmol. 2021 Dec;99(8):826-836. doi: 10.1111/aos.14824. Epub 2021 Mar 08.

Iris-claw lenses have gained increasing popularity over the last years and are by many surgeons regarded as viable options in eyes with insufficient capsular or zonular support. The iris-claw lens has two haptics with fine fissures for folding (enclavating)...

Cite
Drolsum L, Kristianslund O. Implantation of retropupillary iris-claw lenses: A review on surgical management and outcomes. Acta Ophthalmol. 2021;99(8):826-836doi: 10.1111/aos.14824.
Drolsum, L., & Kristianslund, O. (2021). Implantation of retropupillary iris-claw lenses: A review on surgical management and outcomes. Acta ophthalmologica, 99(8), 826-836. https://doi.org/10.1111/aos.14824
Drolsum, Liv, and Kristianslund, Olav. "Implantation of retropupillary iris-claw lenses: A review on surgical management and outcomes." Acta ophthalmologica vol. 99,8 (2021): 826-836. doi: https://doi.org/10.1111/aos.14824
Drolsum L, Kristianslund O. Implantation of retropupillary iris-claw lenses: A review on surgical management and outcomes. Acta Ophthalmol. 2021 Dec;99(8):826-836. doi: 10.1111/aos.14824. Epub 2021 Mar 08. PMID: 33683012.
Copy Download .nbib Format: NLM
Intraocular inflammation in eyes operated for Late In-the-bag intraocular lens dislocation: A randomized clinical trial.

American journal of ophthalmology

Medin H, Dalby M, Kure ISH, Karabeg M, Drolsum L, Kristianslund O.
PMID: 34995522
Am J Ophthalmol. 2022 Jan 04; doi: 10.1016/j.ajo.2021.12.019. Epub 2022 Jan 04.

PURPOSE: To compare the intraocular inflammation after two surgical approaches for late in-the-bag intraocular lens (IOL) dislocation.DESIGN: Prospective, randomized, parallel-group clinical trial.METHODS: We randomly assigned 100 patients (100 eyes) referred to Oslo University Hospital (tertiary referral center) with late...

Cite
Medin H, Dalby M, Kure ISH, et al. Intraocular inflammation in eyes operated for Late In-the-bag intraocular lens dislocation: A randomized clinical trial. Am J Ophthalmol. 2022;doi: 10.1016/j.ajo.2021.12.019.
Medin, H., Dalby, M., Kure, I. S. H., Karabeg, M., Drolsum, L., & Kristianslund, O. (2022). Intraocular inflammation in eyes operated for Late In-the-bag intraocular lens dislocation: A randomized clinical trial. American journal of ophthalmology, . https://doi.org/10.1016/j.ajo.2021.12.019
Medin, Helle, et al. "Intraocular inflammation in eyes operated for Late In-the-bag intraocular lens dislocation: A randomized clinical trial." American journal of ophthalmology vol. (2022). doi: https://doi.org/10.1016/j.ajo.2021.12.019
Medin H, Dalby M, Kure ISH, Karabeg M, Drolsum L, Kristianslund O. Intraocular inflammation in eyes operated for Late In-the-bag intraocular lens dislocation: A randomized clinical trial. Am J Ophthalmol. 2022 Jan 04; doi: 10.1016/j.ajo.2021.12.019. Epub 2022 Jan 04. PMID: 34995522.
Copy Download .nbib Format: NLM
Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study.

RMD open

Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, Krøll F, Rødevand E, Wierød A, Kvien TK, Smolen JS, Aletaha D, Haavardsholm EA.
PMID: 30488000
RMD Open. 2018 Oct 26;4(2):e000773. doi: 10.1136/rmdopen-2018-000773. eCollection 2018.

OBJECTIVE: When initiating a new therapy in patients with rheumatoid arthritis (RA), current treatment recommendations suggest escalating therapy in case of poor clinical improvement by 3 months or if the treatment target has not been reached by 6 months....

Cite
Norvang V, Sexton J, Kristianslund EK, et al. Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. RMD Open. 2018;4(2):e000773doi: 10.1136/rmdopen-2018-000773.
Norvang, V., Sexton, J., Kristianslund, E. K., Olsen, I. C., Uhlig, T., Bakland, G., Krøll, F., Rødevand, E., Wierød, A., Kvien, T. K., Smolen, J. S., Aletaha, D., & Haavardsholm, E. A. (2018). Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. RMD open, 4(2), e000773. https://doi.org/10.1136/rmdopen-2018-000773
Norvang, Vibeke, et al. "Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study." RMD open vol. 4,2 (2018): e000773. doi: https://doi.org/10.1136/rmdopen-2018-000773
Norvang V, Sexton J, Kristianslund EK, Olsen IC, Uhlig T, Bakland G, Krøll F, Rødevand E, Wierød A, Kvien TK, Smolen JS, Aletaha D, Haavardsholm EA. Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. RMD Open. 2018 Oct 26;4(2):e000773. doi: 10.1136/rmdopen-2018-000773. eCollection 2018. PMID: 30488000; PMCID: PMC6242030.
Copy Download .nbib Format: NLM
Prevalence of keratoconus in persons with Down syndrome: a review.

BMJ open ophthalmology

Kristianslund O, Drolsum L.
PMID: 33981858
BMJ Open Ophthalmol. 2021 Apr 21;6(1):e000754. doi: 10.1136/bmjophth-2021-000754. eCollection 2021.

PURPOSE: Keratoconus is a vision-threatening condition, and there is a need for knowledge about the occurrence in subgroups of the population. The progression of the disease can be effectively stopped, and vision may be restored, if keratoconus is diagnosed...

Cite
Kristianslund O, Drolsum L. Prevalence of keratoconus in persons with Down syndrome: a review. BMJ Open Ophthalmol. 2021;6(1):e000754doi: 10.1136/bmjophth-2021-000754.
Kristianslund, O., & Drolsum, L. (2021). Prevalence of keratoconus in persons with Down syndrome: a review. BMJ open ophthalmology, 6(1), e000754. https://doi.org/10.1136/bmjophth-2021-000754
Kristianslund, Olav, and Drolsum, Liv. "Prevalence of keratoconus in persons with Down syndrome: a review." BMJ open ophthalmology vol. 6,1 (2021): e000754. doi: https://doi.org/10.1136/bmjophth-2021-000754
Kristianslund O, Drolsum L. Prevalence of keratoconus in persons with Down syndrome: a review. BMJ Open Ophthalmol. 2021 Apr 21;6(1):e000754. doi: 10.1136/bmjophth-2021-000754. eCollection 2021. PMID: 33981858; PMCID: PMC8061858.
Copy Download .nbib Format: NLM
Prevalence and incidence of keratoconus in Norway: a nationwide register study.

Acta ophthalmologica

Kristianslund O, Hagem AM, Thorsrud A, Drolsum L.
PMID: 33196151
Acta Ophthalmol. 2021 Aug;99(5):e694-e699. doi: 10.1111/aos.14668. Epub 2020 Nov 16.

PURPOSE: To estimate the national prevalence and incidence of keratoconus in Norway.METHODS: In this epidemiologic study, data were obtained from the Norwegian Patient Registry, which provides information from all publicly funded specialist care in Norway. Prevalence of keratoconus was...

Cite
Kristianslund O, Hagem AM, Thorsrud A, et al. Prevalence and incidence of keratoconus in Norway: a nationwide register study. Acta Ophthalmol. 2020;99(5):e694-e699doi: 10.1111/aos.14668.
Kristianslund, O., Hagem, A. M., Thorsrud, A., & Drolsum, L. (2021). Prevalence and incidence of keratoconus in Norway: a nationwide register study. Acta ophthalmologica, 99(5), e694-e699. https://doi.org/10.1111/aos.14668
Kristianslund, Olav, et al. "Prevalence and incidence of keratoconus in Norway: a nationwide register study." Acta ophthalmologica vol. 99,5 (2021): e694-e699. doi: https://doi.org/10.1111/aos.14668
Kristianslund O, Hagem AM, Thorsrud A, Drolsum L. Prevalence and incidence of keratoconus in Norway: a nationwide register study. Acta Ophthalmol. 2021 Aug;99(5):e694-e699. doi: 10.1111/aos.14668. Epub 2020 Nov 16. PMID: 33196151.
Copy Download .nbib Format: NLM
Persistent pupillary membranes and cataract.

American journal of ophthalmology

Kristianslund O, Cholidis S.
PMID: 34175306
Am J Ophthalmol. 2021 Sep;229:e1. doi: 10.1016/j.ajo.2021.05.030. Epub 2021 Jun 24.

No abstract available.

Cite
Kristianslund O, Cholidis S. Persistent pupillary membranes and cataract. Am J Ophthalmol. 2021;229:e1doi: 10.1016/j.ajo.2021.05.030.
Kristianslund, O., & Cholidis, S. (2021). Persistent pupillary membranes and cataract. American journal of ophthalmology, 229e1. https://doi.org/10.1016/j.ajo.2021.05.030
Kristianslund, Olav, and Cholidis, Symira. "Persistent pupillary membranes and cataract." American journal of ophthalmology vol. 229 (2021): e1. doi: https://doi.org/10.1016/j.ajo.2021.05.030
Kristianslund O, Cholidis S. Persistent pupillary membranes and cataract. Am J Ophthalmol. 2021 Sep;229:e1. doi: 10.1016/j.ajo.2021.05.030. Epub 2021 Jun 24. PMID: 34175306.
Copy Download .nbib Format: NLM
Long-term outcome of primary intraocular lens implantation in bilateral congenital cataract in infants with a median age of 35 days at surgery: a case series.

BMJ open ophthalmology

Sand MK, Cholidis S, Rimstad K, Krekling ED, Kristianslund O, Drolsum L.
PMID: 34651084
BMJ Open Ophthalmol. 2021 Sep 30;6(1):e000836. doi: 10.1136/bmjophth-2021-000836. eCollection 2021.

OBJECTIVE: To evaluate the long-term visual outcome and safety after bilateral cataract surgery with primary intraocular lens (IOL) implantation in infants with visually significant cataract at birth operated before 12 weeks of age.METHODS AND ANALYSIS: Medical records of infants...

Cite
Sand MK, Cholidis S, Rimstad K, et al. Long-term outcome of primary intraocular lens implantation in bilateral congenital cataract in infants with a median age of 35 days at surgery: a case series. BMJ Open Ophthalmol. 2021;6(1):e000836doi: 10.1136/bmjophth-2021-000836.
Sand, M. K., Cholidis, S., Rimstad, K., Krekling, E. D., Kristianslund, O., & Drolsum, L. (2021). Long-term outcome of primary intraocular lens implantation in bilateral congenital cataract in infants with a median age of 35 days at surgery: a case series. BMJ open ophthalmology, 6(1), e000836. https://doi.org/10.1136/bmjophth-2021-000836
Sand, Mari Kathrine, et al. "Long-term outcome of primary intraocular lens implantation in bilateral congenital cataract in infants with a median age of 35 days at surgery: a case series." BMJ open ophthalmology vol. 6,1 (2021): e000836. doi: https://doi.org/10.1136/bmjophth-2021-000836
Sand MK, Cholidis S, Rimstad K, Krekling ED, Kristianslund O, Drolsum L. Long-term outcome of primary intraocular lens implantation in bilateral congenital cataract in infants with a median age of 35 days at surgery: a case series. BMJ Open Ophthalmol. 2021 Sep 30;6(1):e000836. doi: 10.1136/bmjophth-2021-000836. eCollection 2021. PMID: 34651084; PMCID: PMC8487206.
Copy Download .nbib Format: NLM
Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries.

Arthritis care & research

Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, Pombo-Suarez M, Mann H, Rotar Z, Eklund KK, Kvien TK, Santos MJ, Gudbjornsson B, Codreanu C, Yilmaz S, Wallman JK, Brahe CH, Möller B, Favalli EG, Sánchez-Piedra C, Nekvindova L, Tomsic M, Trokovic N, Kristianslund EK, Santos H, Löve TJ, Ionescu R, Pehlivan Y, Jones GT, van der Horst-Bruinsma I, Ørnbjerg LM, Østergaard M, Hetland ML.
PMID: 33460531
Arthritis Care Res (Hoboken). 2021 Jan 18; doi: 10.1002/acr.24560. Epub 2021 Jan 18.

OBJECTIVE: There is a lack of real-life studies on IL-17 inhibition in psoriatic arthritis (PsA). We assessed real-life 6-/12-month effectiveness (i.e. retention, remission, low-disease-activity [LDA] and response rates) of the IL-17 inhibitor secukinumab in PsA patients overall, and across...

Cite
Michelsen B, Georgiadis S, Di Giuseppe D, et al. Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries. Arthritis Care Res (Hoboken). 2021;doi: 10.1002/acr.24560.
Michelsen, B., Georgiadis, S., Di Giuseppe, D., Loft, A. G., Nissen, M. J., Iannone, F., Pombo-Suarez, M., Mann, H., Rotar, Z., Eklund, K. K., Kvien, T. K., Santos, M. J., Gudbjornsson, B., Codreanu, C., Yilmaz, S., Wallman, J. K., Brahe, C. H., Möller, B., Favalli, E. G., Sánchez-Piedra, C., Nekvindova, L., Tomsic, M., Trokovic, N., Kristianslund, E. K., Santos, H., Löve, T. J., Ionescu, R., Pehlivan, Y., Jones, G. T., van der Horst-Bruinsma, I., Ørnbjerg, L. M., Østergaard, M., & Hetland, M. L. (2021). Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries. Arthritis care & research, . https://doi.org/10.1002/acr.24560
Michelsen, Brigitte, et al. "Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries." Arthritis care & research vol. (2021). doi: https://doi.org/10.1002/acr.24560
Michelsen B, Georgiadis S, Di Giuseppe D, Loft AG, Nissen MJ, Iannone F, Pombo-Suarez M, Mann H, Rotar Z, Eklund KK, Kvien TK, Santos MJ, Gudbjornsson B, Codreanu C, Yilmaz S, Wallman JK, Brahe CH, Möller B, Favalli EG, Sánchez-Piedra C, Nekvindova L, Tomsic M, Trokovic N, Kristianslund EK, Santos H, Löve TJ, Ionescu R, Pehlivan Y, Jones GT, van der Horst-Bruinsma I, Ørnbjerg LM, Østergaard M, Hetland ML. Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries. Arthritis Care Res (Hoboken). 2021 Jan 18; doi: 10.1002/acr.24560. Epub 2021 Jan 18. PMID: 33460531.
Copy Download .nbib Format: NLM
European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response.

Rheumatology (Oxford, England)

Christiansen SN, Ørnbjerg LM, Horskjær Rasmussen S, Loft AG, Askling J, Iannone F, Zavada J, Michelsen B, Nissen M, Onen F, Santos MJ, Pombo-Suarez M, Relas H, Macfarlane GJ, Tomsic M, Codreanu C, Gudbjornsson B, Van der Horst-Bruinsma I, Di Giuseppe D, Glintborg B, Gremese E, Pavelka K, Kristianslund EK, Ciurea A, Akkoc N, Barcelos A, Sánchez-Piedra C, Peltomaa R, Jones GT, Rotar Z, Ionescu R, Grondal G, Van de Sande MGH, Laas K, Østergaard M, Hetland ML.
PMID: 34940840
Rheumatology (Oxford). 2021 Dec 23; doi: 10.1093/rheumatology/keab945. Epub 2021 Dec 23.

OBJECTIVES: To investigate time trends in baseline characteristics and retention, remission and response rates in bio-naïve axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) patients initiating tumour necrosis factor inhibitor (TNFi) treatment.METHODS: Prospectively collected data on bio-naïve axSpA and PsA...

Cite
Christiansen SN, Ørnbjerg LM, Horskjær Rasmussen S, et al. European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response. Rheumatology (Oxford). 2021;doi: 10.1093/rheumatology/keab945.
Christiansen, S. N., Ørnbjerg, L. M., Horskjær Rasmussen, S., Loft, A. G., Askling, J., Iannone, F., Zavada, J., Michelsen, B., Nissen, M., Onen, F., Santos, M. J., Pombo-Suarez, M., Relas, H., Macfarlane, G. J., Tomsic, M., Codreanu, C., Gudbjornsson, B., Van der Horst-Bruinsma, I., Di Giuseppe, D., Glintborg, B., Gremese, E., Pavelka, K., Kristianslund, E. K., Ciurea, A., Akkoc, N., Barcelos, A., Sánchez-Piedra, C., Peltomaa, R., Jones, G. T., Rotar, Z., Ionescu, R., Grondal, G., Van de Sande, M. G. H., Laas, K., Østergaard, M., & Hetland, M. L. (2021). European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response. Rheumatology (Oxford, England), . https://doi.org/10.1093/rheumatology/keab945
Christiansen, Sara Nysom, et al. "European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response." Rheumatology (Oxford, England) vol. (2021). doi: https://doi.org/10.1093/rheumatology/keab945
Christiansen SN, Ørnbjerg LM, Horskjær Rasmussen S, Loft AG, Askling J, Iannone F, Zavada J, Michelsen B, Nissen M, Onen F, Santos MJ, Pombo-Suarez M, Relas H, Macfarlane GJ, Tomsic M, Codreanu C, Gudbjornsson B, Van der Horst-Bruinsma I, Di Giuseppe D, Glintborg B, Gremese E, Pavelka K, Kristianslund EK, Ciurea A, Akkoc N, Barcelos A, Sánchez-Piedra C, Peltomaa R, Jones GT, Rotar Z, Ionescu R, Grondal G, Van de Sande MGH, Laas K, Østergaard M, Hetland ML. European bio-naïve spondyloarthritis patients initiating TNFi: Time trends in baseline characteristics, treatment retention and response. Rheumatology (Oxford). 2021 Dec 23; doi: 10.1093/rheumatology/keab945. Epub 2021 Dec 23. PMID: 34940840.
Copy Download .nbib Format: NLM
Catalytic enantioselective iodolactonization reactions.

Organic & biomolecular chemistry

Kristianslund R, Tungen JE, Hansen TV.
PMID: 30806424
Org Biomol Chem. 2019 Mar 20;17(12):3079-3092. doi: 10.1039/c8ob03160f.

The halolactonization reaction is a useful chemical transformation for the construction of lactones from γ- or δ-substituted alkenoic carboxylic acids or carboxylic esters. Traditionally, the stereoselectivity of these reactions has been controlled by the substrates or the reagents. The...

Cite
Kristianslund R, Tungen JE, Hansen TV. Catalytic enantioselective iodolactonization reactions. Org Biomol Chem. 2019;17(12):3079-3092doi: 10.1039/c8ob03160f.
Kristianslund, R., Tungen, J. E., & Hansen, T. V. (2019). Catalytic enantioselective iodolactonization reactions. Organic & biomolecular chemistry, 17(12), 3079-3092. https://doi.org/10.1039/c8ob03160f
Kristianslund, Renate, et al. "Catalytic enantioselective iodolactonization reactions." Organic & biomolecular chemistry vol. 17,12 (2019): 3079-3092. doi: https://doi.org/10.1039/c8ob03160f
Kristianslund R, Tungen JE, Hansen TV. Catalytic enantioselective iodolactonization reactions. Org Biomol Chem. 2019 Mar 20;17(12):3079-3092. doi: 10.1039/c8ob03160f. PMID: 30806424.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 14 entries